Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has selected a compound identified in its ongoing collaboration with Pharmacopeia for preclinical development. The compound will be evaluated as a potential treatment for metabolic diseases.
Subscribe to our email newsletter
According to the companies’ collaboration agreement, Schering-Plough is responsible for further development of the compounds. Pharmacopeia is eligible to receive milestone payments if the program advances into late-stage clinical trials and future royalties on sales of resulting products.
Pharmacopeia and Schering-Plough have been collaborating on the discovery of novel compounds, for further R&D by Schering-Plough, since 1994. This latest compound is the collaboration’s sixth drug candidate currently in development.
Presently, Schering-Plough is investigating a CXCR-2 antagonist from the collaboration as a potential treatment for chronic obstructive pulmonary disease (COPD) in phase I clinical trials.
Pharmacopeia currently has twelve partnered compounds in development with major pharmaceutical or biotechnology companies. Eight of these compounds are in preclinical development and four compounds are in phase I clinical trials.